Koral Shah, Hematology/Oncology Chief Fellow at City of Hope, shared a post on X:
“Can genomics help us choose between IO-IO and IO-TKI in metastatic clear cell RCC?
At ASCO2026, we used Concert AI’s Patient360 real-world dataset to compare biomarker-defined outcomes among >1,000 patients tx with 1L IO-based combos.
Many thanks to Sumanta K. Pal for his support.”
Other articles featuring Koral Shah on OncoDaily.